Survodutide is an investigational once-weekly injectable drug developed by Boehringer Ingelheim and Zealand Pharma. It functions as a dual agonist of the glucagon receptor and the GLP-1 receptor, aiming to both reduce appetite and increase energy expenditure.

Weight Loss and Metabolic Efficacy

In clinical trials, survodutide has demonstrated potent weight-loss and metabolic benefits:

• Weight Management: In the Phase 3 SYNCHRONIZE-1 trial for adults with obesity (without diabetes), weekly doses of 3.6 mg and 6.0 mg resulted in significant body weight reductions of up to 12% to 13% at week 76. Earlier Phase 2 studies showed even higher weight reductions of up to ≈ 19% over 46 weeks at higher doses.

• Liver Health: Survodutide targets metabolic dysfunction-associated steatohepatitis (MASH) and fatty liver disease. The Phase 3 SYNCHRONIZE-MASLD trial met its endpoints, with up to 84% of treated patients achieving a clinically meaningful reduction in liver fat content compared to placebo.

Designation and Side Effects

• Regulatory Status: The U.S. FDA has granted survodutide both Fast Track Designation (May 2021) and Breakthrough Therapy Designation (September 2024) for non-cirrhotic MASH and moderate or advanced fibrosis.

• Adverse Events: Like other GLP-1-based medications, the most commonly reported side effects are gastrointestinal (nausea, vomiting, heartburn, constipation, and diarrhea), which typically occur during the dose-escalation phase and are generally mild to moderate.

  
  

For further updates on clinical trials and pipeline progress, you can review the ⁠Boehringer Ingelheim Pipeline or ⁠Zealand Pharma Pipeline.

This is for informational purposes only. For medical advice or diagnosis, consult a professional.

This product for research use only.